Advance Nanotech's Michael Helmus, Ph.D. to Co-Chair Session at ASM International Materials and Medical Devices Conference
|Company Also Announces Recent Release of Book Co-Edited by Dr. Helmus, Medical Device Materials II: Proceedings from the Materials and Processes for Medical Devices 2004|
“Advance has a deep focus in multiple disciplines, including materials and medical applications. A conference like this one, not to mention the work of the AMS, highlights the important convergence of nanotechnology, materials and life sciences which is why we are pleased to have a voice in shaping the discussion.”
Advance Nanotech, Inc., (OTC BB:AVNA.OB), the world's premier provider of services, support and financing to drive the commercialization of nanotechnology discoveries, today announced that its Senior Vice President of BioPharma, Michael Helmus Ph.D., is on the organizing committee and will be co-chairing a major session on Advanced Materials, which includes a substantial focus on nanomaterials, as part of the three day ASM International Materials Processes and Medical Devices Conference held at Boston's Park Plaza Hotel from November 14-16, 2005. He will be presenting a talk on Nanotechnology for Medical Devices: Issues for Commercialization on Wed. Nov. 16.
ASM, previously known as the American Society for Metals, is the society for materials engineers and scientists, a worldwide network dedicated to advancing industry, technology and applications of metals and materials. The major focus of this year's conference is on materials for medical applications, closely linking specialties in materials and biopharma. Dr. Helmus will leverage his deep expertise in biopharma and Advance's focus on materials to shape the discussion.
Advance Nanotech is currently funding 20 portfolio companies in the electronics, biopharma, and materials industries. The firm provides services ranging from funding, to human capital and research equipment essential to ensuring that the most promising companies can accelerate the path to rapid commercialization. In this way, investor exposure to any particular technology is mitigated with Advance Nanotech retaining the option to increase investment in those technologies that successfully mature.
"I am enthusiastic about the opportunity to speak at this important conference," said Dr. Helmus. "Advance has a deep focus in multiple disciplines, including materials and medical applications. A conference like this one, not to mention the work of the AMS, highlights the important convergence of nanotechnology, materials and life sciences which is why we are pleased to have a voice in shaping the discussion.
The book Co-Edited by Dr. Helmus, Medical Device Materials II: Proceedings from The Materials and Processes for Medical Devices 2004 is based on last years meeting and includes manuscripts from the sessions on nano and microfabricated structures for medical devices.
Dr. Helmus, who served as Vice President of Advance Biomaterials at Boston Scientific before joining Advance Nanotech, heads Advance's BioPharma Group. In this capacity, Dr. Helmus is responsible for identifying biopharmaceutical discoveries that can be helped to the market via Advance's commercialization process.
About Advance Nanotech, Inc.
Advance Nanotech Inc. is dedicated to ensuring nanotechnology discoveries reach maximum market potential through successful commercialization. Advance is the trusted guide to commercial success for nanotech entrepreneurs spanning the globe, partnering with leading universities to provide scientists and researchers with mission critical infrastructure support to transform their discoveries to marketable solutions. The organization provides a range of services and support including financing, leadership assets, and counsel on intellectual property, licensing and regulatory issues. With a portfolio of more than 20 companies developing technologies which offer potentially breakthrough nanotechnology discoveries in the electronics, biopharma and materials sectors, Advance's goal is to transform the potential for nanotechnology discoveries into innovative products that further evolve existing industries and enable new markets.